End points evaluated were maximum preinjection IOP during the @-month treatment period ; any occurrence of absolute preinjection IOP of @ mmHg or more , @ mmHg or more , or @ mmHg or more ; any occurrence of IOP increase of @ mmHg or more , @ mmHg or more , or @ mmHg or more from baseline ; any combination of IOP increase of @ mmHg or more or @ mmHg or more from baseline with concurrent absolute preinjection IOP of @ mmHg or more or @ mmHg or more ; glaucoma-related adverse events ; new glaucoma medications used for @ days or more ; and glaucoma filtration or laser surgeries .